Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193945512200014X |
| _version_ | 1811272541398892544 |
|---|---|
| author | Adeeb A. Bulkhi, MD, MSc Ahmad A. Mirza, MBBS, MSc Abdullah J. Aburiziza, MD, ABP Osama A. Marglani, MD, FRCSC |
| author_facet | Adeeb A. Bulkhi, MD, MSc Ahmad A. Mirza, MBBS, MSc Abdullah J. Aburiziza, MD, ABP Osama A. Marglani, MD, FRCSC |
| author_sort | Adeeb A. Bulkhi, MD, MSc |
| collection | DOAJ |
| description | Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test. |
| first_indexed | 2024-04-12T22:42:10Z |
| format | Article |
| id | doaj.art-0057b7b30faa4d4bbee2332ad8511a1e |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-04-12T22:42:10Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-0057b7b30faa4d4bbee2332ad8511a1e2022-12-22T03:13:39ZengElsevierWorld Allergy Organization Journal1939-45512022-03-01153100638Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:Adeeb A. Bulkhi, MD, MSc0Ahmad A. Mirza, MBBS, MSc1Abdullah J. Aburiziza, MD, ABP2Osama A. Marglani, MD, FRCSC3Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, Fl, USA; Department of Allergy and Immunology, King Abdullah Medical City, Makkah, Saudi ArabiaDepartment of Otolaryngology–Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Otolaryngology–Head and Neck Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Corresponding author. Department of Otolaryngology–Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, P.O. Box 80200, Jeddah, 21589, Saudi Arabia.Department of Pediatrics, Umm Al-Qura University (UQU), Makkah, Saudi ArabiaDepartment of Ophthalmology, and Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; Department of Surgery, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi ArabiaAllergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.http://www.sciencedirect.com/science/article/pii/S193945512200014XBiological therapiesHypersensitivityNasal polypSinusitisSaudi Arabia |
| spellingShingle | Adeeb A. Bulkhi, MD, MSc Ahmad A. Mirza, MBBS, MSc Abdullah J. Aburiziza, MD, ABP Osama A. Marglani, MD, FRCSC Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points: World Allergy Organization Journal Biological therapies Hypersensitivity Nasal polyp Sinusitis Saudi Arabia |
| title | Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points: |
| title_full | Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points: |
| title_fullStr | Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points: |
| title_full_unstemmed | Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points: |
| title_short | Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points: |
| title_sort | dupilumab an emerging therapy in allergic fungal rhinosinusitiskey points |
| topic | Biological therapies Hypersensitivity Nasal polyp Sinusitis Saudi Arabia |
| url | http://www.sciencedirect.com/science/article/pii/S193945512200014X |
| work_keys_str_mv | AT adeebabulkhimdmsc dupilumabanemergingtherapyinallergicfungalrhinosinusitiskeypoints AT ahmadamirzambbsmsc dupilumabanemergingtherapyinallergicfungalrhinosinusitiskeypoints AT abdullahjaburizizamdabp dupilumabanemergingtherapyinallergicfungalrhinosinusitiskeypoints AT osamaamarglanimdfrcsc dupilumabanemergingtherapyinallergicfungalrhinosinusitiskeypoints |